Disease relevance of DLEU1

• Lymphoma cells with CD25 (anti-Tac)+, CD5 (Leu1)+, and alkaline phosphatase (ALPase)- in eight cases showed bone marrow involvement (10-66% of the nucleated cells; mean 32 +/- 18%) but with no leukemic changes [1].

High impact information on DLEU1

• From the minimally deleted region, 3 candidate genes have been isolated, RFP2, BCMS, and BCMSUN [2].
• For the two genes residing in the proximal subregion, initially named LEU1 and LEU2, a pathogenic role has not yet been established [3].
• B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions [3].
• This gene, designated B-cell neoplasia-associated gene with multiple splicing (BCMS), is composed of at least 50 exons spanning >or=560 kb of genomic DNA and is expressed in more than 20 RNA splicing variants [3].
• The alignment of the gene with all critical subregions provides a strong argument for BCMS being the most likely candidate for the tumor suppressor gene in 13q14 involved in the leukemogenesis of B-CLL [3].

Biological context of DLEU1

• Mutational analysis of the Leu1 and 2 genes in 170 CLL samples revealed no small intragenic mutations or point mutations [4].
• The Leu1 and Leu2 genes show little homology to previously published genes at the nucleotide and expected translated amino acid sequence level [4].

Other interactions of DLEU1

• Furthermore, our work allowed us to identify new alternative transcripts, spanning core regions, of the previously defined candidate genes DLEU1 and DLEU2 [5].
• Here, we have cloned and characterized a novel gene, DLEU7, located adjacent to the consensus deleted region, and overlapping the 3' end of DLEU1 tail to tail [6].

Analytical, diagnostic and therapeutic context of DLEU1

• Sequence analysis of the RNA variants suggests that BCMS transcripts belong to the group of non-coding RNAs [3].

References